Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 10, 2007, Pages 1114-1120

  Mohammed, A ^a,b   Myer, L ^b   Ehrlich, R ^b   Wood, R ^b   Cilliers, F ^c   Maartens, Gary ^b,d  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Randomised controlled trial; South Africa; Tuberculosis prevention

Indexed keywords

COTRIMOXAZOLE; ISONIAZID; PLACEBO; PYRIDOXINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SPUTUM CULTURE; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; MALE; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 35348966950     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
2. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2004 (1): CD000171.
3. Bucher H C, Griffith L E, Guyat G H, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.
4. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193.
5. Holmes C B, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42: 464-469.
6. Wood R, Maartens G, Lombard C J. Risk factors for developing tuberculosis in HIV-1 infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23: 75-80.
7. Rangaka M X, Wilkinson K A, Seldon R, et al. Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520.
8. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
9. Hawken M P, Meme H K, Elliott L C, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-882.
10. Mwinga A, Hosp M, Godfrey-Fausett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
11. Fitzgerald D W, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001; 28: 305-307.
12. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8: 792-793.
13. Perriens J H, St Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
14. Halsey N A, Coberly J S, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792.
15. Comstock G W. Prevention of tuberculosis among tuberculin reactors: maximising benefits, minimising risks. JAMA 1986; 256: 2729-2730.
16. Grant A, Charalambous S, Fielding K, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293: 2719-2725.
17. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with human immunodeficiency virus. N Engl J Med 1997; 337: 801-808.
18. Rowe K A, Makhubele B, Hargreaves J R, Porter J D, Hausier H P, Pronyk P M. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis 2005; 9: 263-269.
19. Newell J N, Baral S C, Pande S B, Bam D S, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367: 903-909.
20. Manders A J, Banerjee A, van den Borne H W, Harries A D, Kok G J, Salaniponi F M. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase. Int J Tuberc Lung Dis 2001; 5: 838-842.